Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transfer of breast milk IgA to infants after oral bivalent norovirus vaccination of post-partum women.

NPJ vaccines·2026
Same author

Cryo-electron microscopy of the f1 filamentous phage reveals insights into viral infection and assembly.

Nature communications·2023
Same author

Genetically encoded multivalent liquid glycan array displayed on M13 bacteriophage.

Nature chemical biology·2021
Same author

Genetically Encoded Fragment-Based Discovery from Phage-Displayed Macrocyclic Libraries with Genetically Encoded Unnatural Pharmacophores.

Journal of the American Chemical Society·2021
Same author

Humoral Immunodeficiency and Immune Globulin Replacement Therapy (IGRT) Usage in DiGeorge Syndrome.

Journal of clinical immunology·2021
Same author

Hypothermia: A Sign of Sepsis in Young Infants in the Emergency Department?

Pediatric emergency care·2018
Same journal

Monographic Issue on New Concepts in Acute Exacerbations of COPD.

Seminars in respiratory and critical care medicine·2026
Same journal

Bidirectional Clinical Interactions among Exacerbations and Comorbidities in COPD: A Narrative Review.

Seminars in respiratory and critical care medicine·2026
Same journal

Radiological Approach to Severe Respiratory Infections and Pulmonary Complications in Immunocompromised Patients.

Seminars in respiratory and critical care medicine·2026
Same journal

Two Sides of the Same Smoke: Decoding Respiratory Bronchiolitis-Associated Interstitial Lung Disease and Alveolar Macrophage Pneumonia.

Seminars in respiratory and critical care medicine·2026
Same journal

Role of Vaccination in the Prevention of ECOPD.

Seminars in respiratory and critical care medicine·2026
Same journal

Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Pharmacological Treatment of AECOPD New Perspectives.

Seminars in respiratory and critical care medicine·2026
See all related articles

Related Experiment Video

Updated: May 26, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Pneumocystis pneumonia.

Shelley A Gilroy1, Nicholas J Bennett

  • 1Division of Infectious Disease/HIV Medicine, Albany Medical College, Albany, New York 12208, USA. gilroys@mail.amc.edu

Seminars in Respiratory and Critical Care Medicine
|December 15, 2011
PubMed
Summary
This summary is machine-generated.

Pneumocystis jiroveci pneumonia affects immunocompromised individuals, particularly transplant recipients and those with advanced HIV. Diagnosis involves histopathology, and trimethoprim-sulfamethoxazole is the primary treatment.

More Related Videos

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases
03:22

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases

Published on: March 1, 2024

Related Experiment Videos

Last Updated: May 26, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases
03:22

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases

Published on: March 1, 2024

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Immunocompromised Host Infections

Background:

  • Pneumocystis jiroveci pneumonia (PJP) is a significant opportunistic infection.
  • It primarily affects individuals with compromised immune systems, including transplant recipients and those with advanced human immunodeficiency virus (HIV) infection.
  • The organism, initially misclassified, is now recognized as a unicellular fungus responsible for human infections.

Purpose of the Study:

  • To review the characteristics, diagnosis, and treatment of Pneumocystis jiroveci pneumonia.
  • To highlight its prevalence in specific immunocompromised populations.
  • To discuss the diagnostic modalities and therapeutic strategies for PJP.

Main Methods:

  • Review of clinical presentations and epidemiological data.
  • Discussion of diagnostic approaches, including histopathological examination of respiratory samples.
  • Summary of established treatment and prophylaxis regimens.

Main Results:

  • PJP presents with varied clinical courses: slow, indolent pneumonia in HIV-infected patients and fulminant respiratory failure in non-HIV-infected individuals.
  • Definitive diagnosis requires histopathological confirmation.
  • Trimethoprim-sulfamethoxazole is the recommended first-line agent for treatment and prevention.

Conclusions:

  • Pneumocystis jiroveci pneumonia remains a critical infection in immunocompromised patients.
  • Accurate diagnosis through histopathology is essential for timely management.
  • Effective treatment and prophylaxis are available, with trimethoprim-sulfamethoxazole being the standard of care.